Volume 4 Issue 2
Apr.  2013
Turn off MathJax
Article Contents

doi: 10.3969/j.issn.1674-9081.2013.02.022
  • Received Date: 2013-03-25
  • Publish Date: 2013-04-30
  • loading
  • [1] Bahn RS. Graves' ophthalmopathy[J]. N Engl J Med, 2010, 362:726-738. doi:  10.1056/NEJMra0905750
    [2] Khoo DH, Eng PH, Ho SC, et al. Graves' ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels:prevalence, natural history, and thyrotropin receptor antibody levels[J]. Thyroid, 2000, 10:1093-1100. doi:  10.1089/thy.2000.10.1093
    [3] Garrity JA, Babn RS. Pathogenesis of graves' ophthalmopathy:implications for prediction, prevention and treatment[J]. Am J Ophthalmol, 2006, 142:147-153. doi:  10.1016/j.ajo.2006.02.047
    [4] Khalilzadeh O, Noshad S, Rashidi A, et al. Graves' ophthalmopathy:a review of immunogenetics[J]. Curr Genomics, 2011, 12:564-575. doi:  10.2174/138920211798120844
    [5] Trisk F, Tallstedt L, Abraham-Nordling M, et al. Thyroidassociated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131[J]. J Clin Endocrinol Metab, 2009, 94:3700-3707. doi:  10.1210/jc.2009-0747
    [6] Gould DJ, Roth FS, Soparkar CN, et al. The diagnosis and treatment of thyroid-associated ophthalmopathy[J]. Aesthetic Plast Surg, 2012, 36:638-648. doi:  10.1007/s00266-011-9843-4
    [7] Werner SC. Modification of the classification of the eye changes of Graves' disease:recommendations of the Ad Hoc Committee of the American Thyroid Association[J]. J Clin Endocr Metab, 1977, 44:203-204. doi:  10.1210/jcem-44-1-203
    [8] Bartalena L, Baldeschi L, Dickinson AJ, et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO[J]. Eur J Endocrinol, 2008, 158:273-285. doi:  10.1530/EJE-07-0666
    [9] Mourits MP, Koomneef L, Wieminga WM, et al. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy:a novel approach[J]. Br J Ophthalmol, 1989, 73:639-644. doi:  10.1136/bjo.73.8.639
    [10] Pinchera A, Wicminga W, Glinoer D, et al. Classification of eye changes of Graves' disease[J]. Thyroid, 1992, 2:235-236. doi:  10.1089/thy.1992.2.235
    [11] Stan MN, Garrity JA, Bahn RS. The evaluation and treatment of Graves ophthalmopathy[J]. Med Clin North Am, 2012, 96:311-328. doi:  10.1016/j.mcna.2012.01.014
    [12] Eckstein A, Quadbeck B, Mueller G, et al. Impact of smoking on the response to treatment of thyroid associated ophthalmopathy[J]. Br J Ophthalmol, 2003, 87:773-776. doi:  10.1136/bjo.87.6.773
    [13] Weber KJ, Solorzano CC, Lee JK, et al. Thyroidectomy remains an effective treatment option for Graves' disease[J]. Am J Surg, 2006, 191:400-405. doi:  10.1016/j.amjsurg.2005.10.043
    [14] Szucs-Farkas Z, Toth J, Kollar J, et al. Volume changes in intra-and extra orbital compartments in patients with Graves' ophthalmopathy:effect of smoking[J]. Thyroid, 2005, 15:146-151. doi:  10.1089/thy.2005.15.146
    [15] Bartalena L, Tanda ML. Clinical practice of Graves' ophthalmopathy[J]. N Engl J Med, 2009, 360:994-1001. doi:  10.1056/NEJMcp0806317
    [16] Uddin JM, Davies PD. Treatment of upper eyelid retraction associated with thyroid eye disease with subconjunctival botulinum toxin injection[J]. Ophthalmology, 2002, 109:1183-1187. doi:  10.1016/S0161-6420(02)01041-2
    [17] Bartalena L, Marcocci C, Tanda ML, et al. An update on medical management of Graves' ophthalmopathy[J]. J Endocrinol Invest, 2005, 28:469-478. doi:  10.1007/BF03347230
    [18] Kauppinen-Mäkelin R, Karma A, Leinonen E, et al. High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroid-associated ophthalmopathy[J]. Acta Ophthalmol Scand, 2002, 80:316-321. doi:  10.1034/j.1600-0420.2002.800316.x
    [19] Kahaly GJ, Pitz S, Hommel G, et al. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy[J]. J Clin Endocrinol Metab, 2005, 90:5234-5240. doi:  10.1210/jc.2005-0148
    [20] Poonyathalang A, Precchawat P, Charocnkul W, et al. Retrobulbar injection of triameinolone in thyroid associated orbitopathy[J]. J Med Assoc Thai, 2005, 88:345-349.
    [21] Chee E, Chee SP. Subconjunctival injection of triamcinolone in the treatment of lid retraction of patients with thyroid eye disease:a case series[J]. Eye (Lond), 2008, 22:311-315. doi:  10.1038/sj.eye.6702933
    [22] Prummel MF, Mourits MP, Berghout A, et al. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy[J]. N Engl J Med, 1989, 321:1353-1359. doi:  10.1056/NEJM198911163212002
    [23] Tanikawa T, Okada Y, Tanaka Y. Intravenous cyclophosphamide pulse therapy is effective for refractory Graves' ophthalmopathy[J]. J UOEH, 2006, 28:185-191. doi:  10.7888/juoeh.28.185
    [24] Salvi M, Vannucchi G, Campi I, et al. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intra orbital B-cell depletion in one patient unresponsive to steroid immunosuppression[J]. Eur J Endocrinol, 2006, 154:511-517. doi:  10.1530/eje.1.02119
    [25] El Fassi D, Nielsen CH, Hasselbalch HC, et al. Treatmentresistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion[J]. Thyroid, 2006, 16:709-710. doi:  10.1089/thy.2006.16.709
    [26] Khanna D, Chong KK, Afifiyan NF, et al. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy[J]. Ophthalmology, 2010, 117:133-139. doi:  10.1016/j.ophtha.2009.05.029
    [27] Heemstra KA, Toes RE, Sepers J, et al. Rituximab in relapsing Graves' disease, a phase Ⅱ study[J]. Eur J Endocrinol, 2008, 159:609-615. doi:  10.1530/EJE-08-0084
    [28] Finamor FE, Martins JR, Nakanami D, et al. Pentoxifylline (PTX)-an alternative treatment in Graves' ophthalmopathy (inactive phase):assessment by a disease specific quality of life questionaire and by exophthalmometry in a prospective randomized trial[J]. Eur J Ophthalmol, 2004, 14:277-283. doi:  10.1177/112067210401400401
    [29] Cozma I, Zhang L, Uddin J, et al. Modulation of expression of somatostatin receptor subtypes in Graves' ophthalmopathy orbits:relevance to novel analogs[J]. Am J Physiol Endocrinol Metab, 2007, 293:E1630-E1635. doi:  10.1152/ajpendo.00177.2007
    [30] Stan MN, Garrity JA, Bradley EA, et al. Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy[J]. J Clin Endocrinol Metab, 2006, 91:4817-4824. doi:  10.1210/jc.2006-1105
    [31] 吴立兵, 叶方, 刘刚.锝[99Tc]亚甲基二膦酸盐注射液治疗甲状腺功能亢进并发浸润性突眼88例[J].医药导报, 2010, 11:1436-1437.
    [32] 黄艳, 谭兴善.云克与糖皮质激素治疗Graves'眼病的临床分析[J].医学理论与实践, 2008, 21:448-449.
    [33] Bloise W, Mimura LY, Moura J, et al. Treatment of mild to moderate Graves' ophthalmopathy with sodium diclofenac:a pilot study[J]. Arq Bras Endocrinol Metab, 2011, 55:692695.
    [34] Stamato FJ, Maciel RM, Manso PG, et al. Colchicine in the treatment of the inflammatory phase of Graves' ophthalmopathy:a prospective and randomized trial with prednisone[J]. Arq Bras Oftalmol, 2006, 69:811-816. doi:  10.1590/S0004-27492006000600006
    [35] Bouzas EA, Karadimas P, Mastorakos G, et al. Antioxidant agents in the treatment of Graves' ophthalmopathy[J]. Am J Ophthalmol, 2000, 129:618-622. doi:  10.1016/S0002-9394(00)00359-7
    [36] Marcocci C, Kahaly GJ, Krassas GE, et al. Selenium and the course of mild Graves' orbitopathy[J]. N Engl J Med, 2011, 364:1920-1931. doi:  10.1056/NEJMoa1012985
    [37] Bradley EA, Gower EW, Bradley DJ, et al. Orbital radiation for Graves ophthalmopathy:a report by the American Academy of Ophthalmology[J]. Ophthalmology, 2008, 115:398-409. doi:  10.1016/j.ophtha.2007.10.028
    [38] Prummel MF, Terwee CB, Gerding MN, et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy[J]. J Clin Endocrinol Metab, 2004, 89:15-20. doi:  10.1210/jc.2003-030809
    [39] Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin[J]. N Engl J Med, 2001, 345:747-755. doi:  10.1056/NEJMra993360
    [40] Marcocci C, Bartalena L, Tanda ML, et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy:results of a prospective, single-blind, randomized study[J]. J Clin Endocrinol Metab, 2001, 86:3562-3567.
    [41] Bartalena L, Marcocei C, Tanda ML, et al. Orbital radio therapy for Graves' ophthalmopathy[J]. Thyroid, 2002, 12:245-250. doi:  10.1089/105072502753600223
    [42] Boulos PR, Hardy I. Thyroid-associated orbitopathy:a clinicopathologic and therapeutic review[J]. Curr Opin Ophthalmol, 2004, 15:389-400. doi:  10.1097/01.icu.0000139992.15463.1b
    [43] Kurihara H. Total thyroidectomy for the treatment of hyperthyroidism in patients with ophthalmopathy[J]. Thyroid, 2002, 12:265-267. doi:  10.1089/105072502753600250
    [44] Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis:management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists[J]. Thyroid, 2011, 20:593-646. https://pubmed.ncbi.nlm.nih.gov/21510801/
    [45] Wakelkamp IM, Baldeschi L, Saeed P, et al. Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves' ophthalmopathy? A randomized controlled trial[J]. Clin Endocrinol, 2005, 63:323-328. doi:  10.1111/j.1365-2265.2005.02345.x
    [46] Wiersinga WM. Management of Graves' ophthalmopathy[J]. Nat Clin Pract Endocrinol Metab, 2007, 3:396-404. doi:  10.1038/ncpendmet0497
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (260) PDF downloads(8) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return